Therapeutic inhibition of BET proteins provides a unique opportunity to simultaneously target both the stromal and neoplastic cells of PDAC.
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Translational Relevance: Pancreatic ductal adenocarcinoma is extraordinarily chemoresistant and the abundant stromal content of these tumors contributes to the ineffective treatment of this disease. Current approaches in the treatment of PDAC are largely ineffective and utilize drugs that target either the neoplastic cells or the stroma of this disease. This study reveals the broad dependence of pancreatic cancer cell lines and tumor models on the activity of the BET family of chromatin adaptors. BET proteins contribute to PDAC biology by regulating multiple key nodal pathways of this disease, including the direct and indirect regulation of GLI, a family of transcription factors that plays key roles in both epithelial and stromal cells of PDAC tumors.
Therapeutic inhibition of BET proteins provides a unique opportunity to simultaneously target both the stromal and neoplastic cells of PDAC.
INTRODUCTION
The overall five-year survival for PDAC is only 6%, nearly two-thirds lower than any other cancer (1) . In addition to their extraordinary chemoresistance, PDAC tumors contain a highly desmoplastic stroma that is a major impediment to the treatment of this disease. This stroma not only promotes the aggressive local growth of the tumor and the intrinsic chemoresistance of the cancer cells, but also acts as a physical barrier to effective chemotherapeutic targeting (2) . Clearly, future advances in the treatment of PDAC will require therapeutics that are more effective at killing the cancer cells as well as those that effectively target tumor stroma.
The genetic alterations contributing to PDAC pathogenesis have been extensively studied. The predominant mechanism for the formation of PDAC is through the oncogenic conversion of acinar cells (3) . Activating mutations in KRAS initiate acinar-to-ductal metaplasia, with mutations in CDKN2A, TP53, and SMAD4 occurring during progression from pre-neoplastic PanIN lesions to invasive cancer (4) . While recent large scale sequencing studies have provided a detailed view of the spectrum of mutations present in subsets of PDAC, these efforts have yet to identify genes that may be therapeutically targeted (5, 6) . Histone modifications and subsequent chromatin remodeling function as master regulators of gene expression. This regulation is largely mediated by the reversible methylation or acetylation of the tails of histone proteins, and enzymes involved in addition and removal of these modifications are associated with a wide variety of cancers (7) . There is also a growing body of evidence linking the proteins recognizing these epigenetic marks to the maintenance and progression of cancer. In this regard, mutations in chromatin regulators (e.g. SWI/SNF components) are present in approximately 20% of PDAC tumors; however, these mutations all involve inactivation of tumor suppressors, and do not readily suggest therapeutic approaches.
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In this study we employed an in vivo RNAi screen of a library of epigenetic regulators to functionally identify key mediators of PDAC pathogenesis. shRNAs specific for BRD2 and BRD3, members of the BET family of chromatin adaptors, were identified in a dropout screen performed in an orthotopic model of PDAC. BET proteins contain tandem bromodomains that allow for their binding to acetylated lysines on target proteins to regulate gene expression.
Pharmacological inhibition of BET bromodomain binding revealed a critical role of this family in the growth of PDAC cell lines in vitro as well as the in vivo growth of tumors. We found that BET family members regulate PDAC tumor cell growth by modulating the expression of MYC and the activity of the GLI family of transcription factors through direct physical interaction. BET proteins also regulate the tumor microenvironment, at least in part, through the regulation of SHH expression and secretion in the cancer cells.
MATERIALS AND METHODS

Cell Culture
PDAC cell lines were cultured in a 1:1 mix of DMEM and Ham's F-12 media (Mediatech) supplemented with 10% fetal bovine serum (Life Technologies), penicillin (100 U/ml), and streptomycin (100 μg/ml) at 37°C in 5% CO 2 Research. Fig. S1A) . A pooled lentiviral library expressing these shRNAs was used to infect PDAC cell lines and 24-48 hrs after infection, cells were implanted into pancreata of mice and allowed to form orthotopic tumors (Fig. 1A) . Depleted shRNAs were identified by comparing the relative abundance of an shRNA in the tumor to that of the original population of infected cells (Fig. 1B, Supplementary Fig. S1B and C, and Supplementary Table   S1 ). Identified in this screen were BRD2 and BRD3, members of the BET family of chromatin adaptor proteins. At least two shRNAs targeting each of these genes were depleted more than 15-fold in tumors derived from each cell line.
To begin to understand the role of BET family members in PDAC tumorigenesis, their expression in normal pancreas and malignant tissue was analyzed employing a tissue microarray containing 121 surgically resected pancreatic specimens, including 91 unique PDAC samples ( Fig. 1C and Supplementary Fig. S2 ) (13) . Consistent with their identification in the in vivo shRNA screen, elevated nuclear expression of BRD2 and BRD3 was observed in premalignant and malignant tissue relative to normal pancreas. Weak nuclear expression of BRD2 was observed in the vast majority of normal acinar cell samples. Upon undergoing acinar-toductal metaplasia (ADM), cells expressed higher nuclear BRD2 levels (p<0.013) that were comparable to that observed in normal ductal epithelium. This increase in BRD2 levels was maintained in primary and metastatic tumors (n=121, p<0.003). Nuclear expression of BRD3 was rarely observed in normal acinar cells but was strongly expressed in the nuclei of cells undergoing ADM (p<0.001) and cells throughout PanIN progression (n=22, p<0.001) to primary and metastatic disease (n=92, p<0.004). In contrast to BRD2 and BRD3, nuclear BRD4 expression was readily detected in normal acinar and duct cells, as well as cells throughout the histological progression to cancer. No significant differences in the staining of BRD4 were observed between these samples.
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Pharmacological inhibition of BET proteins impairs PDAC cell growth
To evaluate the contribution of BET proteins to in vitro growth of PDAC cells, we employed the BET bromodomain inhibitor CPI203 (BETi). This small molecule acts by competitively inhibiting the binding of BET bromodomains to acetylated lysines (14) . Nineteen PDAC cell lines, including 15 low-passage cell lines derived from xenograft tumors, were treated with increasing amounts (0-6.4 μM) of BETi to evaluate their effects on cell growth ( Fig. 2A) .
Eighty-four percent of the cell lines tested were responsive to BET bromodomain inhibition (GI 50 < 1 μM) ( Supplementary Fig. S3A ), but not to treatment with the inactive enantiomer, CPI440
(data not shown). PDAC cells had a mean GI 50 of 510 nM and, based on their deviation from the mean, cell lines were defined as exhibiting high (GI 50 < 350 nM), intermediate (GI 50 < 600 nM), or low sensitivity to BETi (GI 50 > 1 μM). Similar differences in the effects of BETi on high and low sensitivity cells were observed with a second BET bromodomain inhibitor, JQ1
( Supplementary Fig. S3B ). These groups generally exhibited an inverse correlation between BETi sensitivity and the percentage of residual cell viability observed at the maximum dose of BETi (Fig. 2B) , likely reflecting differing heterogeneity of the cell populations. Sensitivity to BET bromodomain inhibition between the cell lines appeared to be independent of relative BRD2, BRD3, or BRD4 expression levels ( Supplementary Fig. S3C ).
To further interrogate the effects of BET bromodomain inhibition, the growth kinetics of high and low sensitivity cell lines were analyzed (Fig. 2C ). High sensitivity cell lines (722, 1108, and BxPc3) exhibited a nearly five-fold growth difference after five days whereas low sensitivity PANC-1 showed only a 2-fold reduction in growth. Increases in apoptosis were not observed in cells after treatment with BETi (data not shown). However, cell cycle analysis revealed BETi induced an increase in the proportion of cells in G1 in high sensitivity cell lines, whereas the cell cycle distribution in low sensitivity cells was not altered (Fig. 2D) 
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G1 to S transition revealed increased abundance of p27 Kip1, a negative regulator of cyclin dependent kinases (CDKs), in high sensitivity cells treated with BETi (Supplemental Fig. S3D ).
Consistent with this, levels of phosphorylated Rb (Ser780) were decreased in these cells.
Interestingly, total levels of Rb were also diminished by BETi, suggesting a secondary mechanism by which BET bromodomain inhibition affects cell cycle progression. In accordance with our cell cycle analysis, these alterations in p27 Kip1, phospho-RB, and total Rb were not observed in low sensitivity PANC-1 cells.
BET regulation of MYC contributes to the biology of PDAC
To determine the mechanism(s) by which BET proteins contribute to PDAC cell growth, Fig 3D) . These results are consistent with previous observations that BET proteins regulate MYC expression in a subset of PDAC cells (15, 16) .
To support the potential role of MYC inhibition in the response to BETi, we tested the impact of three shRNAs targeting MYC on PDAC cell growth (Fig. 3E) . Each MYC-specific shRNA reduced the proliferation of three high sensitivity cell lines, although the effects were considerably weaker than BETi (Fig. 3F) 
BET proteins regulate GLI activity in PDAC
Our GSEA also suggested a prominent role for BET proteins in the regulation of the SHH-GLI signaling pathway ( Fig. 3B and Fig. 4A ). This pathway has dual roles in PDAC, cell autonomous functions for GLI proteins in PDAC cell growth, and a distinct paracrine function of SHH produced by PDAC cells in the proliferation of the stroma (17, 18) . Therefore, the SHHspecific gene sets identified in our GSEA likely reflect SHH-independent alterations in GLI activity in PDAC cells. Consistent with this hypothesis, a significant overlap between BETresponsive genes and those dependent on GLI activity was observed ( Fig. S4C ). Importantly, these reductions in gene expression correlated with decreased GLI activity in PDAC cells. Employing a luciferase reporter vector driven by a GLI-dependent promoter, we observed greater than 60% decrease in GLI-luciferase activity after 24 hours of BET bromodomain inhibition in four PDAC cell lines ( Fig. 4C and Supplementary Fig. S4D and E). Additionally, this change in GLI activity exhibited a dose-dependent response to BETi, with as little as 100 nM of BETi suppressing GLIluciferase activity by 50% or more. These results demonstrate that BET proteins play a key role in maintaining the activity of GLI in PDAC cells and diminished GLI activity likely contributes to the biological effects of BETi.
To understand the mechanisms by which BET proteins regulate the activity of GLI, we examined the effects of BETi on the expression GLI. qPCR analysis revealed dramatic decreases in GLI1 mRNA levels in the majority of cell lines exposed to BETi for 24 hours ( Supplementary Fig. S5A ). GLI2 mRNA levels were also diminished in half of these cell lines. Greater than 50% reductions in GLI1 and GLI2 mRNA are seen between 4-8 hours of BET bromodomain inhibition ( Supplementary Fig. S5B ). Despite this, little to no decrease in their protein levels occurred after 24 hours (Fig. 4D) , a time by which GLI-luciferase activity and expression of GLI target genes are diminished. Protein half-life studies revealed that the discrepancy between GLI RNA and proteins levels was due to an increased GLI protein half-life after BET bromodomain inhibition. While GLI1 and GLI2 half-life is 4-8 hours in control cells, little change in their protein levels are observed in BETi treated cells even after 24 hours of protein synthesis inhibition ( Supplementary Fig. S5C ). Taken together, these results suggest that suppression of the GLI transcriptional program in PDAC cells by BET bromodomain inhibition is not due to reduced expression of GLI1 and GLI2.
The lack of significant changes in the proteins levels of GLI1, GLI2, and GLI3
( Supplementary Fig. S5D ) after BET bromodomain inhibition suggested that the observed reductions in GLI target gene expression and GLI-luciferase activity is due to a direct regulation of GLI by BET proteins. Co-immunoprecipitation experiments were performed to determine whether BET and GLI proteins are found in the same protein complexes. In PDAC cells ectopically expressing GLI1, immunoprecipitations of BRD2, BRD3, and BRD4 resulted in the co-precipitation of GLI1 (Fig. 4E) . Reciprocal experiments using antibodies specific to GLI1 identified the co-precipitation BRD4 ( Supplementary Fig. S6A ). Furthermore, this interaction between GLI1 and BRD4 was diminished by BET bromodomain inhibition ( 
BET bromodomain activity is required for PDAC tumor growth
To directly examine whether BET proteins are required for the growth of PDAC tumors in vivo, we evaluated the effects of BETi on the growth of xenograft tumors derived from human PDAC cell lines. Mice bearing heterotopic tumors were treated with BETi (10 mg/kg) or vehicle control twice daily using a 5-days on;2-days off dosing regimen. On average, tumors in control mice continued to grow to five times their starting size while tumors in mice treated with BETi exhibited little to no growth (Fig. 5A, p<0.05 and 5B, p<0.03). Importantly, immunostaining with a human ki67-specific antibody revealed a 60% reduction (p<0.001) in proliferation of the ;p53 -/-mice form highly aggressive PDAC by 6 weeks of age and have an average survival of 60 days ( Fig. 5D ) (8) . Administering BETi to these mice after tumor formation (at 6 weeks of age) prolonged their average survival to more than 71 days (p<0.006).
Notably, at the time of necropsy, tumors from BETi treated mice were six times smaller (p<0.003) than those from control mice (Fig. 5E ). Despite this dramatic reduction in tumor burden, the death of BETi-treated mice appeared to be cancer related, as tumors from BETi treated mice frequently obstructed the intrapancreatic bile duct and non tumor-bearing mice treated with BETi for 28 days did not exhibit evidence of cytotoxicity (data not shown).
Consistent with that observed for xenograft tumors, an 80% decrease (p<0.02) in the proliferation of cytokeratin-positive tumor cells was observed in BETi treated mice relative to controls (Fig. 5F ). There was no appreciable difference in the histology of tumors from control and BETi treated mice as tumors in both groups were moderate to poorly differentiated and contained cells with a mesenchymal morphology ( Supplementary Fig. S7A ).
BET bromodomain activity regulates key pathways for PDAC tumor growth and maintenance of the tumor microenvironment
Research. Given the robust effect of BET bromodomain inhibition on the growth of PDAC tumor models, we examined whether the BET-regulated pathways identified in PDAC cell lines are also altered in tumors. Mice bearing orthotopic PDAC tumors were treated with BETi or vehicle control for three days, and RNA from tumors were examined for changes in gene expression.
The expression of MYC was reduced by 45% (p<0.05) in mice treated with BETi relative to control mice. Additionally, the expression of GLI target genes was decreased 54-80% (p<0.03) after BET bromodomain inhibition, consistent with a reduction in GLI activity in the cancer cells.
Furthermore, an 80% decrease (p<0.04) in SHH was observed in the human-derived cancer cells from mice treated with BETi relative to those from control mice (Fig. 6C) . Consistent with suppression of SHH signaling, the expression of canonical hedgehog target genes, Gli1 and Fig S7C) which is consistent with the expression of BET proteins in the cancer associated fibroblasts of human PDAC samples (Supplemental Fig S7D) .
Nevertheless, these results define an important role for BET bromodomain activity in the maintenance of the cancer associated fibroblasts in both murine and human tumor models of PDAC.
BRD2 and BRD4 regulate the SHH-GLI pathway
To evaluate the contribution of individual BET proteins to the effects of BET bromodomain inhibition, we employed shRNAs targeting BRD2, BRD3, and BRD4 in two lowpassage cell lines that were highly sensitive to BETi, 722 and 1108. Each shRNA effectively diminished the expression of the corresponding BET protein in these cells (Supplemental Fig   S9A and B) . Western blots analyzing the effects of two shRNAs targeting each BET family member revealed a key role for BRD2, BRD3, and BRD4 in the expression of MYC (Supplemental Fig S10A and B) . However, one BRD2-specific shRNA (5240) Here we demonstrated that GLI transcriptional activity is dependent on BET bromodomain activity in PDAC cells. GLI1 and GL2 physically interact with BRD2, BRD3, and BRD4, defining a novel mechanism for the regulation of GLI activity. Since BET proteins have been found to be components of the super elongation complex and polymerase-associated factor complex, it is likely that they contribute to GLI transcriptional activity by mediating the release of paused RNA PolII on the promoters of GLI target genes (19) . Acetylated lysines in both GLI1 (K518) and GLI2 (K757) regulate their transcriptional activity (20, 21) . However, only the interaction of GLI1 and BET proteins was sensitive to BETi, indicating that GLI1-BET complexes are largely responsible for the bromodomain-dependent GLI activity observed in PDAC cells and suggests a bromodomain-independent mechanism by which BET proteins associate with GLI2.
Decreases in GLI activity after BET bromodomain inhibition have also been reported in mouse fibroblasts and mouse models of medulloblastoma (22, 23) . However these changes in GLI activity involve the direct regulation of GLI mRNA expression and ultimate control of corresponding protein levels by BET proteins. In PDAC cells, GLI protein levels remain unchanged after short-term BET bromodomain inhibition due to an extended protein half-life.
While the mechanism for this increased protein stability is unknown, it is possible that GLI exhibits decreased stability when it is part of BET complexes to allow for tighter transcriptional regulation of GLI target genes. While this increased protein stability is unlikely to overcome the The significance of the GLI transcriptional program to PDAC has recently become apparent.
GLI activity in neoplastic cells of PDAC is independent of canonical SHH signaling (24) . The mechanism by which GLI is activated in PDAC cells is unclear, but involves KRAS and TGFβ (17, 25) . Inhibition of GLI activity by shRNA or a dominant negative mutant of GLI (Gli-3T) in human PDAC cells resulted in reduced soft agar colony formation (17, 25) . Incorporation of Gli-3T in mouse models of PDAC revealed that GLI activity is required for the formation of 
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The role of the SHH-dependent stroma in PDAC has been somewhat controversial. Initial studies inhibiting SHH signaling demonstrated a collapse of the tumor stroma, enhanced tumor vascularity, and increased delivery of gemcitabine to tumors (31) . This study suggested that depletion of the stroma would allow for more effective deliver drugs to the tumor. However, subsequent studies have revealed that the stroma also plays an important role in restraining the growth of the tumor (23, 30, 32) . Depletion of cancer associated fibroblasts in GEM models of PDAC result in poorly differentiated tumors that are more aggressive and less responsive to chemotherapy. Thus, the tumor stroma of PDAC presents a conundrum; its presence enhances the chemoresistance of the cancer cells but its absence results in a more aggressive disease.
Perhaps methods that more modestly reduce the tumor stoma, as demonstrated here with BET bromodomain inhibition, may shift the balance towards a favorable therapeutic outcome.
Additionally, therapies that involve the depletion of the tumor stroma may need to be combined with those that are effective at treating more aggressive, poorly differentiated tumors. BET bromodomain inhibition may be one such therapy, as it was highly effective in treating poorly differentiated and moderate to poorly differentiated xenograft and GEM model of PDAC employed in our studies.
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